Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer
Authors:
- B. GlimeliusBGB. Glimelius
- R. RistamäkiRRR. Ristamäki
- M. KjaerMKM. Kjaer
- P. PfeifferPPP. Pfeiffer
- T. SkovsgaardTST. Skovsgaard
- K. M. TveitKTK. M. Tveit
- T. LinnéTLT. Linné
- J. E. FrödinJFJ. E. Frödin
- B. BoussardBBB. Boussard
- D. Oulid-AïssaDOD. Oulid-Aïssa
- S. PyrhönenSPS. Pyrhönen
Open Access
- 1 December 2002
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 13 (12) , 1868-1873
Abstract
Background: This multicentre phase II study evaluated the efficacy and safety of irinotecan combined with the Nordic schedule of 5-fluorouracil (5-FU) and folinic acid (FA) as first-line therapy in patients with advanced colorectal cancer. Patients and methods: Seventy-four patients with measurable disease and a WHO performance status of 2 or less were treated with irinotecan 210 mg/m2 as a 30–90 min intravenous infusion on day 1, followed by 5-FU 500 mg/m2 and FA 60 mg/m2 bolus on days 1 and 2, every 2 weeks, until disease progression or unacceptable toxicity. The primary end point was the objective response rate. Results: Twenty-nine out of 68 evaluable patients achieved a complete (n = 7) or partial (n = 22) response, leading to an overall response rate of 43% [95% confidence interval (CI) 31% to 55%]. The median duration of response was 10 months. The estimated median time to progression and survival were 6.4 months (95% CI 5.4–9.0) and 15.6 months (95% CI 13.3–19.0), respectively, in the intention-to-treat population. A total of 860 cycles were administered to 74 patients. Neutropenia was the main adverse event with grade 3–4 toxicity in 66% of patients and 17.5% of cycles. Grade 3–4 non-haematological toxicities were infrequent and included diarrhoea in 16% of patients and 2% of cycles and nausea/vomiting in 10% of patients and 1% of cycles. Conclusions: Irinotecan combined with the bolus Nordic schedule of 5-FU/FA is active in advanced colorectal cancer with an easily managed safety profile which ensures good schedule compliance. The low incidence of grade 3–4 non-haematological toxicity justifies the further evaluation of this combination in the context of randomised clinical trials.Keywords
This publication has 17 references indexed in Scilit:
- Dose-effect Relationship of Bolus 5-Fluorouracil in the Treatment of Advanced Colorectal CancerActa Oncologica, 2002
- Mortality Associated With Irinotecan Plus Bolus Fluorouracil/Leucovorin: Summary Findings of an Independent PanelJournal of Clinical Oncology, 2001
- Recommendation for Caution with Irinotecan, Fluorouracil, and Leucovorin for Colorectal CancerNew England Journal of Medicine, 2001
- A Systematic Overview of Chemotherapy Effects in Colorectal CancerActa Oncologica, 2001
- Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2000
- Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancerThe Lancet, 1998
- Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancerThe Lancet, 1998
- Bolus injection (2–4min) versus short-term (10–20min) infusion of 5-fluorouracil in patients with advanced colorectal cancer: a prospective randomised trialEuropean Journal of Cancer, 1998
- CPT-11 (Irinotecan) in the treatment of colorectal cancerEuropean Journal of Cancer, 1995
- Topoisomerase I inhibitors: topotecan and irenotecanCancer Treatment Reviews, 1994